Skip to main content
Premium Trial:

Request an Annual Quote

IDbyDNA/Illumina RUO Respiratory Pathogen ID/AMR Target Enrichment Panel

IDbyDNA and Illumina this week launched their codeveloped Respiratory Pathogen ID/AMR Target Enrichment Panel for research use only. Developed under a previously announced strategic partnership between the companies, the panel uses IDbyDNA's Explify software platform and Illumina's next-generation sequencing technology to detect more than 280 respiratory pathogens (bacterial, viral, and fungal) as well as genes associated with more than 1,200 antimicrobial resistance markers. Using Illumina's MiniSeq Rapid Reagent Kit, the panel can deliver results in less than 24 hours. IDbyDNA's Explify database includes millions of curated DNA and RNA reference sequences and can identify more than 50,000 microorganisms and more than 6,000 known common and rare pathogens, including antimicrobial resistance.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.